Stressgen - 500 Beiträge pro Seite
eröffnet am 09.03.00 01:10:27 von
neuester Beitrag 14.03.00 02:59:23 von
neuester Beitrag 14.03.00 02:59:23 von
Beiträge: 10
ID: 90.103
ID: 90.103
Aufrufe heute: 0
Gesamt: 684
Gesamt: 684
Aktive User: 0
ISIN: US40624Q3020 · WKN: A3D38X · Symbol: HALL
0,0014
USD
-99,78 %
-0,6486 USD
Letzter Kurs 02:10:00 Nasdaq OTC
Werte aus der Branche Finanzdienstleistungen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6550 | +43,17 | |
| 1,4600 | +43,14 | |
| 1,5400 | +21,26 | |
| 0,6650 | +16,67 | |
| 2,0450 | +16,03 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 6,6600 | -9,88 | |
| 30,85 | -9,93 | |
| 14,750 | -14,14 | |
| 1.138,25 | -16,86 | |
| 1,0750 | -21,82 |
Feedback
Stressgen heute + 35% in Toronto. Die Rallye beginnt - morgen auch in Frankfurt und in Stuttgart.
Kursziel: 15 Euro.
Kursziel: 15 Euro.
HALLO HILLYBE WO KANN MAN KURSE AUS TORONTO ABFRAGEN.WÄRE NETT
WENN DU MIR DAS MIT TEILEN WÜRDEST.DANK IM VORAUS.
WENN DU MIR DAS MIT TEILEN WÜRDEST.DANK IM VORAUS.
Der Kurs kann unter yahoo abgefragt werden. Einfach die Lookup-Funktion benutzen, um das Kürzel zu bekommen.
www.tse.com
VIELEN DANK LEUTE.
Trading Spotlight
Hallo Leute,
über diese www. könnt Ihr direkt die news zu stressgen abfragen, es sieht gut aus...
quelle_01:
http://www.stockhouse.ca/comp_info.asp?symbol=SSB&table=list…?symbol=SSB&table=list" target="_blank" rel="nofollow ugc noopener">http://www.stockhouse.ca/comp_info.asp?symbol=SSB&table=list…?symbol=SSB&table=list
quelle_02
http://www.stockhouse.ca/comp_info.asp?symbol=SSB&table=list…
mfg
mschu
über diese www. könnt Ihr direkt die news zu stressgen abfragen, es sieht gut aus...
quelle_01:
http://www.stockhouse.ca/comp_info.asp?symbol=SSB&table=list…?symbol=SSB&table=list" target="_blank" rel="nofollow ugc noopener">http://www.stockhouse.ca/comp_info.asp?symbol=SSB&table=list…?symbol=SSB&table=list
quelle_02
http://www.stockhouse.ca/comp_info.asp?symbol=SSB&table=list…
mfg
mschu
13.03.00 Stockhouse-News:
http://www.stockhouse.ca/comp_info.asp?symbol=SSB&table=list…
http://www.stockhouse.ca/comp_info.asp?symbol=SSB&table=list…
Van_Sun
StressGen Loss Increases To $16.7 Million
Van_Sun - 3/11/00 5:13:04 PM
Vancouver Sun
Investment in research and product development contributed to a loss at StressGen Biotechnologies Corp. [T.SSB] of $16.7 million or 55 cents a share in 1999 compared with $14.2 million or 57 cents a share in the previous year.
Revenues slipped to $4 million from $4.5 million.
Chief financial officer Dave Matthews said spending including its lead product aimed at non-surgical treatment for abnormal cervical tissue.
The Victoria-based biotechnology company also announced the appointment of Daniel Korpolinski as president and chief executive officer of its U.S. operations.
"Daniel Korpolinski`s appointment strengthens the company`s management team at a time when increased emphasis is being placed on commercialization and partnering strategies due to the rapid maturation of the product portfolio," StressGen president and chief executive officer Richard Glickman said.
Korpolinski will eventually assume the role of StressGen`s chief executive officer and Glickman will become vice-chair of the board of directors.
"This is the first step in the company`s strategy toward moving into the U.S. financial market and fortifying the company`s management as it enters a more mature stage of development," Glickman said.
He said key objectives include the creations of corporate alliances with major pharmaceutical companies, an enhanced presence in the U.S. pharmaceutical and financial community and a listing on a U.S. exchange.
Separately, Immune Network Research Ltd. [V.IMM] said it has closed a private placement of $8.5 million with Groome Capital.com Inc.
"This financing allows Immune Network to move aggressively forward with adding value to our current product line," Immune Network CEO Dr. Allen Bain said. "We are in the business of creating rapid return on investments in drug discovery and we now have the financial strength to realize the potential of our business model."
The Vancouver company is developing antibody-based therapeutics.
Another local company, Angiotech Pharmaceuticals, Inc. [T.ANP], said it has received a $1.8-million milestone payment from Boston Scientific Corp. [BSX], an international medical-device manufacturer.
The payment was triggered by Boston Scientific`s filing of regulatory documents to initiate clinical studies of Angiotech`s anti-inflammatory treatments.
It is the second in a series of potential payments to Angiotech under a co-exclusive worldwide licensing agreement with Boston Scientific and Cook Inc.
Cook made the first payment of $1.8 million to Angiotech in early January. Under the licensing agreement, Angiotech could receive up to $32 million.
StressGen Loss Increases To $16.7 Million
Van_Sun - 3/11/00 5:13:04 PM
Vancouver Sun
Investment in research and product development contributed to a loss at StressGen Biotechnologies Corp. [T.SSB] of $16.7 million or 55 cents a share in 1999 compared with $14.2 million or 57 cents a share in the previous year.
Revenues slipped to $4 million from $4.5 million.
Chief financial officer Dave Matthews said spending including its lead product aimed at non-surgical treatment for abnormal cervical tissue.
The Victoria-based biotechnology company also announced the appointment of Daniel Korpolinski as president and chief executive officer of its U.S. operations.
"Daniel Korpolinski`s appointment strengthens the company`s management team at a time when increased emphasis is being placed on commercialization and partnering strategies due to the rapid maturation of the product portfolio," StressGen president and chief executive officer Richard Glickman said.
Korpolinski will eventually assume the role of StressGen`s chief executive officer and Glickman will become vice-chair of the board of directors.
"This is the first step in the company`s strategy toward moving into the U.S. financial market and fortifying the company`s management as it enters a more mature stage of development," Glickman said.
He said key objectives include the creations of corporate alliances with major pharmaceutical companies, an enhanced presence in the U.S. pharmaceutical and financial community and a listing on a U.S. exchange.
Separately, Immune Network Research Ltd. [V.IMM] said it has closed a private placement of $8.5 million with Groome Capital.com Inc.
"This financing allows Immune Network to move aggressively forward with adding value to our current product line," Immune Network CEO Dr. Allen Bain said. "We are in the business of creating rapid return on investments in drug discovery and we now have the financial strength to realize the potential of our business model."
The Vancouver company is developing antibody-based therapeutics.
Another local company, Angiotech Pharmaceuticals, Inc. [T.ANP], said it has received a $1.8-million milestone payment from Boston Scientific Corp. [BSX], an international medical-device manufacturer.
The payment was triggered by Boston Scientific`s filing of regulatory documents to initiate clinical studies of Angiotech`s anti-inflammatory treatments.
It is the second in a series of potential payments to Angiotech under a co-exclusive worldwide licensing agreement with Boston Scientific and Cook Inc.
Cook made the first payment of $1.8 million to Angiotech in early January. Under the licensing agreement, Angiotech could receive up to $32 million.
06.03. Biotech Report :
STRESSGEN Top- Empfehlung aus Canada: Kurzziel 20-30 CAD.
Eine seidenheisse Top Emphehlung erhielt unser New Yorker Büro kurz vor Redaktionsschluß von Kollegen aus Toronto: In einer Resaerchstudie des Investmenthauses Nesbitt Burns rechnen die Analysten mit einer Kursverdreifachung bei STRESSGEN BIOTECH! Auch die jüngste Kursentwicklung zeigt, dass Sie hier sofort einige Käufe plazieren müssen, nachdem der Kurs die Wiederstandslinie bei CAD 7 wie Butter durchstossen hat. STRESSGGEN ist eine kanadische Krebsforschungsgesellschaft, die durch Stress Signalen oser Hitzeschock Proteine zur Bekämphung entarteter Krebszellen entwickelt. Das Hauptproduckt hat den Code HspE7. Experten erwarten in den kommenden Monaten sensationelle Neuigkeiten. Der Kurs hat bereits reagiert Und dennoch: Die in ähnlichen Bereichen tätige ANTIGENICS hat eine Marktkapitalisierung, die siebenmal höher isr. Nesbitt Burns sieht eine faire Bewertung bei CAD 760 Mio., was den Aktienkurs von CAD 19 bedeuten würde. Kaufen Sie hier unbedingt. In Deutschland aber bitte streng limitieren, grössere Orders nach Toronto legen!
(EUR 7.4, WKN 901062, Börse Frankfurt, Reuters SSB)
STRESSGEN Top- Empfehlung aus Canada: Kurzziel 20-30 CAD.
Eine seidenheisse Top Emphehlung erhielt unser New Yorker Büro kurz vor Redaktionsschluß von Kollegen aus Toronto: In einer Resaerchstudie des Investmenthauses Nesbitt Burns rechnen die Analysten mit einer Kursverdreifachung bei STRESSGEN BIOTECH! Auch die jüngste Kursentwicklung zeigt, dass Sie hier sofort einige Käufe plazieren müssen, nachdem der Kurs die Wiederstandslinie bei CAD 7 wie Butter durchstossen hat. STRESSGGEN ist eine kanadische Krebsforschungsgesellschaft, die durch Stress Signalen oser Hitzeschock Proteine zur Bekämphung entarteter Krebszellen entwickelt. Das Hauptproduckt hat den Code HspE7. Experten erwarten in den kommenden Monaten sensationelle Neuigkeiten. Der Kurs hat bereits reagiert Und dennoch: Die in ähnlichen Bereichen tätige ANTIGENICS hat eine Marktkapitalisierung, die siebenmal höher isr. Nesbitt Burns sieht eine faire Bewertung bei CAD 760 Mio., was den Aktienkurs von CAD 19 bedeuten würde. Kaufen Sie hier unbedingt. In Deutschland aber bitte streng limitieren, grössere Orders nach Toronto legen!
(EUR 7.4, WKN 901062, Börse Frankfurt, Reuters SSB)
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +1,67 | |
| +0,37 | |
| -0,09 | |
| -1,03 | |
| -0,07 | |
| +13,04 | |
| -0,75 | |
| +1,77 | |
| +0,12 | |
| +0,48 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 297 | ||
| 106 | ||
| 106 | ||
| 106 | ||
| 83 | ||
| 59 | ||
| 54 | ||
| 48 | ||
| 43 | ||
| 42 |
